Avacincaptad pegol, FLUORESCEIN clinical trials

AN OPEN-LABEL EXTENSION (OLE) PHASE 3 TRIAL TO ASSESS THE SAFETY OF INTRAVITREAL ADMINISTRATION OF AVACINCAPTAD PEGOL (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY WHO PREVIOUSLY COMPLETED PHASE 3 STUDY ISEE2008 (GATHER2)

This study is looking at the long-term safety of a medicine called Avacincaptad pegol for people with a serious eye condition called geographic atrophy. It's for those who have already been in a previous study using this medicine.